Literature DB >> 826205

Immunotherapy of cancer with cell wall skeleton of Myocabacterium bovis-Bacillus Calmette-Guérin: experimental and clinical results.

Y Yamamura, I Azuma, T Taniyama, K Sugimura, F Hirao, R Tokuzen, M Okabe, W Nakahara, K Yasumoto, M Ohta.   

Abstract

Adjuvant and antitumor activities of CWS prepared from cells of mycobacteria, nocardia, and corynebacteria were examined. Oil-attached CWS of M. bovis BCG (BCG-CWS) stimulated the generation of cell-mediated cytotoxic effector cells in mice. Tumor growth was suppressed in mice inoculated intradermally with a mixture of oil-attached CWS and living tumor cells. Systemic and specific tumor immunity was demonstrated in mice in which tumor growth was suppressed. Tumor growth was also suppressed by oil-attached CWS of BCG or N. rubra in autochthonous autografts of spontaneous mammary adenocarcinoma and methylcholanthrene-induced fibrosarcoma in mice. The intravenous injection of oil-attached BCG-CWS prevents the appearance of lung cancer in rabbits by the instillation of chemical carcinogens. It was also shown that treatment with oil-attached BCG-CWS was able to elevate the immunologically depressed state of tumor-bearing mice to a normal level, as determined by a cell-mediated cytotoxicity assay that empolyed chromium release as the standard. Preliminary results suggest that oil-attached BCG-CWS is useful as an immunotherapeutic agent for both lung cancer and for malignant melanoma, leukemia, Hodgkin's disease, and other neoplastic diseases and that this agent operates without any significant complications.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 826205     DOI: 10.1111/j.1749-6632.1976.tb41699.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Long-term survival after removal of primary intracranial malignant melanoma. Case report.

Authors:  H Nakagawa; T Hayakawa; K Niiyama; Y Nii; T Yoshimine; S Mori
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

2.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

3.  Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial).

Authors:  H M Jansen; T H The; G C de Gast; M T Esselink; A M van der Wal; N G Orie
Journal:  Thorax       Date:  1978-08       Impact factor: 9.139

4.  Failure of C3H mice to develop lung granuloma after intravenous injection of BCG cell wall vaccine. Demonstration of a defect in lymphoid cells.

Authors:  M Kakinuma; K Onoé; M Okada; T Kimura; K Kato; H Okuyama; K Morikawa; K Yamamoto
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

5.  Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan.

Authors:  Junji Uehori; Misako Matsumoto; Shoutaro Tsuji; Takashi Akazawa; Osamu Takeuchi; Shizuo Akira; Tsutomu Kawata; Ichiro Azuma; Kumao Toyoshima; Tsukasa Seya
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

Review 6.  Role of neutrophils in BCG immunotherapy for bladder cancer.

Authors:  Mark P Simons; Michael A O'Donnell; Thomas S Griffith
Journal:  Urol Oncol       Date:  2008 Jul-Aug       Impact factor: 3.498

7.  Liposome-Encapsulated Bacillus Calmette-Guérin Cell Wall Skeleton Enhances Antitumor Efficiency for Bladder Cancer In Vitro and In Vivo via Induction of AMP-Activated Protein Kinase.

Authors:  Young Mi Whang; Da Hyeon Yoon; Gwang Yong Hwang; Hoyub Yoon; Serk In Park; Young Wook Choi; In Ho Chang
Journal:  Cancers (Basel)       Date:  2020-12-08       Impact factor: 6.639

8.  Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors.

Authors:  S Tsuji; M Matsumoto; O Takeuchi; S Akira; I Azuma; A Hayashi; K Toyoshima; T Seya
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.